Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for MCVEF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 24.00%
March 31, 2026 23.58%
December 31, 2025 22.41%
September 30, 2025 23.46%
June 30, 2025 23.81%
March 31, 2025 22.95%
December 31, 2024 21.72%
September 30, 2024 21.43%
June 30, 2024 21.57%
March 31, 2024 20.97%
December 31, 2023 18.62%
September 30, 2023 21.38%
June 30, 2023 21.05%
March 31, 2023 21.42%
December 31, 2022 20.74%
September 30, 2022 22.14%
June 30, 2022 21.45%
March 31, 2022 25.54%
December 31, 2021 29.02%
September 30, 2021 25.55%
June 30, 2021 29.66%
Date Value
March 31, 2021 30.49%
December 31, 2020 26.74%
September 30, 2020 28.91%
June 30, 2020 24.35%
March 31, 2020 24.96%
December 31, 2019 23.42%
September 30, 2019 24.99%
June 30, 2019 24.10%
March 31, 2019 25.59%
December 31, 2018 24.28%
September 30, 2018 24.13%
June 30, 2018 24.58%
March 31, 2018 24.89%
December 31, 2017 23.77%
September 30, 2017 25.28%
June 30, 2017 24.36%
March 31, 2017 24.47%
December 31, 2016 24.60%
September 30, 2016 24.50%
June 30, 2016 23.44%
March 31, 2016 24.00%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Quest Diagnostics, Inc. 32.53%
Labcorp Holdings, Inc. 27.71%
OPKO Health, Inc. 37.32%
Psychemedics Corp. --
NeoGenomics, Inc. 44.06%